Rupatadine 10 and 20 mg are effective and safe in the treatment of perennial allergic rhinitis after 4 weeks of treatment: A randomized, double-blind, controlled trial with loratadine and placebo

Therapy

Volumn 6, Issue 3, 2009, Pages 417-425

  Kowalski, Marek L ^a   Jurkiewicz, Dariusz ^b   Kruszewski, Jerzy ^c   Nowak, Dariusz ^d   Zietkowski, Ziemowit ^e   Špičaková, Marie ^f   Vernerová, Eva ^g   Seberová, Ester ^h   Klenha, Kamil ⁱ   Izquierdo, Iñaki ⁱ  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c Institute of Internal Medicine   (Poland)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^f Faculty Hospital Kralouske   (Czech Republic)

^g Clinic of Immunology and Allergology   (Czech Republic)

^h NONE

ⁱ J Uriach y Compania   (Spain)

Author keywords

Clinical trial; Histamine H1 antagonists; Perennial allergic rhinitis; Platelet activating factor; Rupatadine

Indexed keywords

LORATADINE; PLACEBO; RUPATADINE; THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FACE EDEMA; FATIGUE; FEMALE; HEART PROARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERENNIAL RHINITIS; PRURITUS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SYMPTOMATOLOGY; TREATMENT DURATION;

EID: 69449085933     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.1     Document Type: Article

References (25)

1. Bousquet J, Van Cauwenberge P, Khaltaev N: Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 108(5 Suppl.), S147-S334 (2001).
2. International Consensus Report on Diagnosis and Management of Rhinitis. International Rhinitis Management Working Group. Allergy 49(19 Suppl.), 1-34 (1994).
3. Bauchau V, Durham SR: Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. Allergy 60(3), 350-353 (2005).
4. Bauchau V, Durham SR: Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur. Respir. J. 24, 758-764 (2004).
5. Rimpela AH, Savonius B, Rimpela MK, Haahtela T: Asthma and allergic rhinitis among Finnish adolescents in 1977-1991. Scand. J. Soc. Med. 23(1), 60-65 (1995).
6. Wang DY, Clement P: Pathogenic mechanisms underlying the clinical symptoms of allergic rhinitis. Am. J. Rhinol. 14(5), 325-333 (2000).
7. Punnonen J, Aversa G, Vanderkerckhove B, Roncarolo M-G, de Vries JE: Induction of isotype switching and Ig production by CD5+ and CD10+ human fetal B cells. J. Immunol. 148, 3398-3404 (1992).
8. Jutel M, Blaser K, Akdis CA: Histamine in allergic inflammation and immune modulation. Int. Arch. Allergy Immunol. 137(1), 82-92 (2005).
9. Yamada Y, Yokota M: Roles of plasma platelet-activating factor acetylhydrolase in allergic, inflammatory, and atherosclerotic diseases. Jpn Circ. J. 62, 328-335 (1998).
10. Petersen LJ, Church MK, Skov PS: Platelet- activating factor induces histamine release from human mast cells in vivo, which is reduced by local nerve blockade. J. Allergy Clin. Immunol. 99, 640-647 (1997).
11. Merlos M, Giral M, Balsa D et al.: Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J. Pharmacol. Exp. Ther. 280(1), 114-121 (1997).
12. Stuebner P, Horak F, Zieglmayer R et al.: Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber. Ann. Allergy Asthma Immunol. 96(1), 37-44 (2006).
13. Martínez-Cócera C, De Molina M, Martí-Guadaño E et al.: Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J. Investig. Allergol. Clin. Immunol. 15(1), 22-29 (2005).
14. Guadaño EM, Serra-Batlles J, Meseguer J et al.: Rupatadine 10 mg and ebastine 10 mg in seasonal allergic rhinitis: a comparison study. Allergy 59(7), 766-771 (2004).
15. Saint-Martin F, Dumur JP, Pérez I, Izquierdo I: A randomized, double-blind, parallel-group study, comparing the ef?cacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J. Investig. Allergol. Clin. Immunol. 14(1), 34-40 (2004).
16. Fantin S, Maspero J, Bisbal C et al.: A 12-week-placebo controlled study of rupatadine 10 mg once daily comparative with cetirizine 10 mg once daily, in the treatment of persistent allergic rhinitis. Allergy 63(7), 924-931 (2008).
17. Bousquet J, Khaltaev N, Cruz AA et al.: Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63(Suppl. 86), 8-160 (2008).
18. Frolund L, Etholm B, Irander K et al.: A multicentre study of loratadine, clemastine and placebo in patients with perennial allergic rhinitis. Allergy 45(4), 254-261 (1990).
19. Bruttmann G, Charpin D, Germouty J, Horak F, Kunkel G, Wittmann G: Evaluation of the efficacy and safety of loratadine in perennial allergic rhinitis. J. Allergy Clin. Immunol. 83, 411-416 (1989).
20. Mullol J, Bousquet J, Bachert C et al.:. Rupatadine in allergic rhinitis and chronic urticaria. Allergy 63(Suppl. 87), 5-28 (2008).
21. Leurs R, Church MK, Taglialatela M: H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin. Exp. Allergy 32(4), 489-498 (2002).
22. Prescott SM, Zimmerman GA, McIntyre TM: The production of platelet-activating factor by cultured human endothelial cells: regulation and function. In: Platelet Activating Factor and Related Lipid Mediators. Synder (Ed.). Plenum Press, NY, USA 323-340 (1987).
23. Bachert C: The role of histamine in allergic disease: re-appraisal of its in?ammatory potential. Allergy 57(4), 287-296 (2002).
24. Izquierdo I, Merlos M, García-Rafanell J: A new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. Drugs Today (Barc). 39(6), 451-468 (2003).
25. Frèche C, Leynadier F, Horak F et al.: Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine. Ann. Allergy Asthma Immunol. 89, 304-310 (2002).